Dosing and Receptors: Lessons Learned from CATIE
Premiere Date: Wednesday, January 25, 2006This activity offers CE credit for:
- Physicians (ACCME/AMA PRA Category 1)
- Nurses (ANCC)
- Pharmacists (ACPE)
- Psychologists (APA)
- Social Workers (NASW)
- Certified Case Managers (CCMC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, January 25, 2007
Note: Credit Is No Longer Available
| Prakash S. Masand, MD Consulting Professor of Psychiatry Duke University Medical Center Durham, NC |
 | Jeffrey A. Lieberman, MD President, American Psyichiatric Association Lawrence C. Kolb Professor and Chairman, Department of Psychiatry College of Physicians and Surgeons, Columbia University Director, New York State Psychiatric Institute Psychiatrist-in-Chief at New York Presbyterian Hospital & Columbia University Medical Center New York, NY |
 | John W. Newcomer, MD Senior Associate Dean for Clinical Research Leonard M. Miller Professor of Psychiatry and Behavioral Sciences Leonard M. Miller School of Medicine University of Miami Miami, FL |
In the past 10 years, five new atypical antipsychotic medications have been FDA-approved as a treatment for schizophrenia. They are collectively placed in the class of atypical, or second-generation, antipsychotics because they all share some advantages over older, first-generation antipsychotics. The distinguishing feature of second-generation antipsychotics is their lower propensity for causing extrapyramidal side effects. They also appear to have a broader spectrum of efficacy in reducing both positive symptoms (hallucinations and delusions) and negative symptoms (amotivation, emotional and social withdrawal), cognitive impairment, mood problems, and perhaps even persistent aggressive behavior. This broader efficacy may be due to differences in the agents’ receptor activity profile. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial is the most comprehensive independent trial comparing existing treatments for schizophrenia conducted thus far; however, information available from CATIE on dosing and two newer atypical antipsychotics, ziprasidone and aripiprazole, is limited. In this evidence-based psychCME TV activity, CATIE researchers will discuss these limitations in the context of receptor pharmacology of the atypical antipsychotics and what it means for the clinicians who are responsible for making informed, real-world decisions on dosing in patients with schizophrenia.
Meltzer HY. What’s atypical about antipsychotic drugs? Curr Opin Pharmacology 2004;4:53-57.
Leiberman et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22;353(12): 1209-23.
To provide evidence-based educational information and clinical context regarding the efficacy of medications used to treat schizophrenia in the CATIE trial.
At the end of this CE activity, participants should be able to:
- Compare and contrast receptor pharmacology of the atypical antipsychotics.
- Assess the relationship of receptor pharmacology to dosing, efficacy, and side effects.
- Apply a contextual framework to the existing CATIE data.
- Recognize the importance of providing individualized treatment strategies for patients with schizophrenia.
Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, and other healthcare professionals with an interest in mental health.
CME Credit (Physicians):
CME Outfitters, LLC, is
accredited by the Accreditation Council for Continuing
Medical Education to provide continuing medical
education for physicians.
CME Outfitters, LLC, designates this educational activity
for a maximum of 1.0 category 1 credits toward the AMA
Physician’s Recognition Award. Each physician should
claim only those credits that he/she actually spent in the
activity.
CNE Credit (Nurses):
This Educational Activity is
presented by CME Outfitters, LLC, which has been
approved as a provider of continuing education by
the New York State Nurses Association, an accredited
approver by the American Nurses Credentialing Center’s
Commission on Accreditation. It has been assigned code
5UYSJZ-PRV-0485. 1.0 contact hour (Pharmacology)
CEP Credit (Psychologists):
CME Outfitters, LLC,
is approved by the American Psychological Association
to offer continuing education for psychologists. CME
Outfitters, LLC, maintains responsibility for the program.
1.0 CE credits
NASW Credit (Social Workers):
This program was
approved by the National Association of Social Workers
(provider #886407722) for 1 continuing education
contact hour.
CCMC Credit (Certified Case Managers):
This
program has been approved for 1 hour by the
Commission for Case Manager Certification (CCMC).
CPE Credit (Pharmacists):
CME Outfitters, LLC,
is accredited by the Accreditation Council
for Pharmacy Education as a provider of
continuing pharmacy education.
1.0 contact hours (0.1 CEUs)
Universal Program Number:
376-999-06-005-L01 (live presentation)
376-999-06-005-H01 (recorded programs)
To receive credit, participants must review all activity
materials in their entirety, score 70% or above on a posttest,
and fully complete and return both the credit request
form and activity evaluation. A certificate or statement
of credit will be mailed within 4-6 weeks to all who
successfully complete these requirements.
Disclosure Declaration
All faculty participating in CME Outfitters continuing education activities are required to disclose any conflict(s) of interest related to the content of their presentation(s) as defined by the ACCME's Standards for Commercial Support, and other accrediting and regulatory bodies. Full disclosure of faculty relationships will be made on this website and within the activity course materials prior to the premiere date of this activity.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
TV-033-012506-08
